TWI284130B - New derivatives of purine, their preparation process, their use as medicaments, pharmaceutical compositions and new use - Google Patents

New derivatives of purine, their preparation process, their use as medicaments, pharmaceutical compositions and new use Download PDF

Info

Publication number
TWI284130B
TWI284130B TW089108817A TW89108817A TWI284130B TW I284130 B TWI284130 B TW I284130B TW 089108817 A TW089108817 A TW 089108817A TW 89108817 A TW89108817 A TW 89108817A TW I284130 B TWI284130 B TW I284130B
Authority
TW
Taiwan
Prior art keywords
group
formula
trans
product
cyclopentyl
Prior art date
Application number
TW089108817A
Other languages
English (en)
Chinese (zh)
Inventor
Jean-Luc Haesslein
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of TWI284130B publication Critical patent/TWI284130B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW089108817A 1999-05-21 2000-05-09 New derivatives of purine, their preparation process, their use as medicaments, pharmaceutical compositions and new use TWI284130B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Publications (1)

Publication Number Publication Date
TWI284130B true TWI284130B (en) 2007-07-21

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089108817A TWI284130B (en) 1999-05-21 2000-05-09 New derivatives of purine, their preparation process, their use as medicaments, pharmaceutical compositions and new use

Country Status (33)

Country Link
US (2) US7122669B1 (enExample)
EP (1) EP1183256B1 (enExample)
JP (1) JP2003500407A (enExample)
KR (1) KR100707895B1 (enExample)
CN (1) CN1298719C (enExample)
AP (1) AP1477A (enExample)
AR (1) AR035317A1 (enExample)
AT (1) ATE370951T1 (enExample)
AU (1) AU4764500A (enExample)
BR (1) BR0011282A (enExample)
CA (1) CA2374714A1 (enExample)
CZ (1) CZ20014163A3 (enExample)
DE (1) DE60036102T2 (enExample)
DK (1) DK1183256T3 (enExample)
DZ (1) DZ3166A1 (enExample)
EA (1) EA005072B1 (enExample)
ES (1) ES2290033T3 (enExample)
FR (1) FR2793794B1 (enExample)
HU (1) HUP0201649A3 (enExample)
IL (1) IL146441A0 (enExample)
MA (1) MA26791A1 (enExample)
MX (1) MXPA01011834A (enExample)
NO (1) NO20015659L (enExample)
NZ (1) NZ515556A (enExample)
PL (1) PL352293A1 (enExample)
PT (1) PT1183256E (enExample)
SK (1) SK16722001A3 (enExample)
TR (1) TR200103349T2 (enExample)
TW (1) TWI284130B (enExample)
UA (1) UA68441C2 (enExample)
WO (1) WO2000071543A1 (enExample)
YU (1) YU86601A (enExample)
ZA (1) ZA200109602B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
EP1377579B1 (en) * 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
EA200101224A1 (ru) 2002-10-31
NZ515556A (en) 2003-08-29
HUP0201649A3 (en) 2003-01-28
US7208598B2 (en) 2007-04-24
UA68441C2 (en) 2004-08-16
EA005072B1 (ru) 2004-10-28
YU86601A (sh) 2005-07-19
ATE370951T1 (de) 2007-09-15
TR200103349T2 (tr) 2002-05-21
EP1183256A1 (fr) 2002-03-06
DE60036102T2 (de) 2008-05-15
JP2003500407A (ja) 2003-01-07
ES2290033T3 (es) 2008-02-16
IL146441A0 (en) 2002-07-25
DE60036102D1 (de) 2007-10-04
US20050187228A1 (en) 2005-08-25
BR0011282A (pt) 2002-02-26
AP2001002355A0 (en) 2001-12-31
CN1298719C (zh) 2007-02-07
MXPA01011834A (es) 2002-04-17
NO20015659D0 (no) 2001-11-20
PL352293A1 (en) 2003-08-11
ZA200109602B (en) 2003-01-29
NO20015659L (no) 2002-01-18
AP1477A (en) 2005-10-19
US7122669B1 (en) 2006-10-17
CA2374714A1 (fr) 2000-11-30
WO2000071543A1 (fr) 2000-11-30
FR2793794A1 (fr) 2000-11-24
HUP0201649A2 (en) 2002-08-28
MA26791A1 (fr) 2004-12-20
CZ20014163A3 (cs) 2002-10-16
KR20010113975A (ko) 2001-12-28
AU4764500A (en) 2000-12-12
KR100707895B1 (ko) 2007-04-17
PT1183256E (pt) 2007-11-13
CN1361780A (zh) 2002-07-31
DK1183256T3 (da) 2007-12-03
EP1183256B1 (fr) 2007-08-22
SK16722001A3 (sk) 2003-01-09
AR035317A1 (es) 2004-05-12
DZ3166A1 (fr) 2000-11-30
FR2793794B1 (fr) 2001-07-27

Similar Documents

Publication Publication Date Title
AU2017252460B2 (en) EZH2 inhibitors and uses thereof
TW307747B (enExample)
CN110177581B (zh) 髓过氧化物酶显像剂
DE60027011T2 (de) Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren
HUP0201545A2 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
BR122019020471B1 (pt) Inibidores da desmetilase específica para lisina 1, seus usos e método para sua identificação, e composições farmacêuticas
RS57331B1 (sr) Inhibitori demetilaze za lsd1 zasnovani na arilciklopropilaminu i njihova medicinska upotreba
EA004263B1 (ru) АГОНИСТЫ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА
CN103130737B (zh) 环己烷胺类化合物及其作为抗精神分裂症药物的应用
WO2011042217A1 (en) Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
US7122669B1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
US8962670B2 (en) Anti-cancer agents
MXPA04008317A (es) Hidroxietilaminas sustituidas.
CN100582084C (zh) 疏水性多胺类似物及其使用方法
WO2023065606A1 (zh) 新型氘代氰基类化合物、其制备方法、组合物及应用
CA3127453A1 (en) Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
JP2024539268A (ja) Sik3阻害剤及びその中間体を調製する合成スキーム及び手順
CN100374441C (zh) 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途
US20250296953A1 (en) 3,4-thiazolo-steroids and methods of making and using the same
Elkamhawy et al. Pyrazinyl ureas revisited: 1-(3-(Benzyloxy) pyrazin-2-yl)-3-(3, 4-dichlorophenyl) urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease
DE60021859T2 (de) 1, 2, 3, 4-tetrahydro-1-naphthalenamin verbindungen zur therapeutsichen verwendung
AU2008201086B2 (en) Hydrophobic Polyamine Analogs and Methods for their Use
EP4255425A1 (en) Imidazole compounds as inhibitors of enpp1
HK40097855A (en) Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same
WO2026044975A1 (zh) 基于热休克蛋白90的二价抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees